Antibiotics, medicinal plants, superbugs and the coming antimicrobial resistant drugs pandemic : global markets, competitors and opportuninites - 2014 - 2019 Analysis and Forecasts

News provided by

Sep 03, 2014, 02:37 ET

LONDON, Sept. 3, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Antibiotics, medicinal plants, superbugs and the coming antimicrobial resistant drugs pandemic : global markets, competitors and opportuninites - 2014 - 2019 Analysis and Forecasts

https://www.reportbuyer.com/product/2116087/Antibiotics-medicinal-plants-superbugs-and-the-coming-antimicrobial-resistant-drugs-pandemic--global-markets-competitors-and-opportuninites---2014---2019-Analysis-and-Forecasts.html

An Antibiotic is an agent that either kills or inhibits the growth of a microorganism. The world is now facing a grave situation: it is losing the battle against infectious diseases; bacteria are fighting back and are becoming resistant to modern medicine; in short, pharmaceutical drugs don't work. If resistance is allowed to increase, in a few decades people may start dying from the most commonplace of ailments that today can be treated easily. In fact, the ability of organisms to develop resistance to the effects of antimicrobial therapies developed to kill them is potentially the greatest challenge to healthcare in the 21st century.

Antimicrobial resistance (AMR) is a form of drug resistance whereby some sub-populations of a microorganism, usually a bacterial species, are able to survive after exposure to one or more antibiotics. Pathogens resistant to multiple antibiotics are considered multidrug resistant (MDR) or, more colloquially, superbugs.

The US and world are in the beginning of an emerging crisis of Antibiotic resistance for microbial pathogens. Epidemic antibiotic resistance has been described in numerous pathogens in varying contexts, including, but not limited to: MRSA (methicillin-resistant Staphylococcus aureus), common respiratory pathogens, including Streptococcus pneumoniae and Mycobacterium tuberculosis, and epidemic increases in multidrug-resistant and, increasingly, truly pan-resistant, gram-negative bacilli.

Why is the level of concern increasing now? It is because the increase in organisms resistant to multiple therapies is now coinciding with the reduction in new therapies coming to market to replace ineffective ones.

Herbal medicine, including medicinal plants, was the only way people could treat infectious diseases until the early 20th century. Since then, pharmaceutical drugs have become the main method for treating bacterial infections. However, the pharmaceutical drug pipeline is almost dry. At the same time, growing consumer awareness of the benefits of herbal medicine, along with a backlash against the exorbitant prices and dangerous side effects of pharmaceutical drugs, have led to a renaissance in the use of medicinal plants. Consumers are starting to focus on keeping healthy rather than dealing with acute situations that require the use of expensive pharmaceutical drugs. Medicinal plants fit perfectly into this new paradigm. And for this reason, their use is forecast to grow dramatically.

This report looks at the use of medicinal plants, rather than Antibiotics, to both treat and prevent bacterial infections.

Specifically, it provides:

• A detailed look at Antibiotics and Antimicrobial Resistant drugs.
• Analysis of the Antibiotics market.
• In-depth examination of Antibacterial Medicinal Plants.
• Analysis of the Medicinal Plants market.

Additionally, profiles of 127 private and public companies involved in the Antibiotics and Medicinal Plants industries as producers, distributors, and retailers are given. The report also includes 32 tables and 32 figures.

INTRODUCTION

- Background, Spread of MRSA to Households, New Delhi Metallo, Consumers Moving Toward Herbal Medicine, Mainstream Medical Establishments Changing Their Thinking, Consumer Focus Now on Maintaining Health, Outlook for Medicinal Plants Vs. Antibiotic Drugs
- Report Objectives
- Methodology and Sources
- Statistical Notes

EXECUTIVE SUMMARY

ANTIBIOTICS AND ANTIMICROBIAL RESISTANT DRUGS

- Antibiotics
- Antibiotic Resistance
- Epidemic of Antibiotic-Resistant Infections
- Grave Situation
- Modern Healthcare Built on Antimicrobials
- History of Antimicrobial Resistance
- Putting the Problem in Context
- Fallacy of Antibiotic Overuse
- Decreasing Antibiotic Development
- Increasing Costs, Decreasing ROI
- Lack of FDA Guidance
- Companies Developing New Antibiotic Drugs
- Government Efforts
- Multi-Drug Resistance Growing
- Current Situation
- Number of AMR Cases Each Year by Type
- More Needs to Be Done
- Incentive Problems
- Economic Costs
- Cost of MRSA
- Paradox of Low Impact
- Limits of Costs of Resistance Assessments
- Outlook
- Reducing Uncertainty and Increasing Knowledge
- Developing Better Incentives
- International Activity

ANTIBIOTICS MARKET OVERVIEW

- Total Market
- Market by Type
- Market by Region
- Market by Application
- Market Commoditization
- Competitive Environment
- Market Opportunities
- Gram-negative Market
- Clostridium difficile-Associated Diarrhea (CDAD)
- Market Landscape for CDAD Treatments
- Fecal Matter Transplants (FMTs)
- Gram-positive Market

PROSPECTS FOR PLANT-DERIVED ANTIBACTERIALS

- Historical Context
- Single-Ingredient Drugs
- Big Pharma Lost Interest in Plants 20 Years Ago
- Need for New Strategies
- Case Against Plants
- Need for New Technologies
- FDA and Botanical Drugs
- First Botanical Drug NDA
- First Oral Botanical Drug NDA
- Future of Botanical Drug Products in the US
- International Botanical Drugs
- Why Biological Drugs Are Needed
- Future of Botanical Drugs in the US
- Scarcity of Disease in Wild Plants
- Why New Antimicrobial Substances from Plants
- Plants as a Source of Antimicrobials
- Plants Synthesize Target-Specific Antibacterials
- Synergy and Multidrug Resistance Pump Inhibitors
- Plant Antibacterials Function in Synergy
- Targeting Bacterial Virulence
- Future Directions
- Plant Antibacterials
- MDR Inhibitors
- Block Pathogen Virulence
- Antimicrobial Resistance and Phytochemicals
- New Therapy Against Resistance
- Phytotherapy
- Phytochemicals and Their Classes
- Secondary Metabolites
- Phenolics and Polyphenols
- Mode of Action of Phytochemicals
- Biofilms and Phytochemicals
- Quorum-Sensing
- Phytochemical Products as Antimicrobials and in Biofilm Control
- Anti-staphylococcal Plant Natural Products
- Resistance Modifying Agents
- Methicillin-resistance Reversing Agents
- Modulators of Multidrug Resistance
- Antibacterial Natural Products
- Topical Materials
- Biological Warfare
- List of Antimicrobial Plants

MEDICINAL PLANT MARKET

- Market Size Estimation Issues
- Global Medicinal Plant Production
- Global Medicinal Plant Exports
- Global Medicinal Plant Imports
- Global Medicinal Plant Production by Type
- Competitive Environment

COMPANY PROFILES

A.A. Sayia & Company, Inc.
A. Baur & Co (Pvt.) Ltd.
Adam Group
Adams Extract & Spice, LLC,
Afriplex
Akbar Brothers Ltd.
Alchem International
Alvita Tea
Ambo Exports
A. M. Todd Botanical Therapeutics, LLC
Asian Tea & Exports Ltd.
Balaji Agro International
Bart Ingredients Company Ltd
Bigelow Tea Company
Bio Foods Pvt Ltd
Brassica Teas
Cape Natural Tea Products
Ceylon Black Tea Company
Ceylon Spice Company
C.F. Sauer Company
Chamong Tee Exports Pvt. Ltd.
Choice Organic Teas
Coetzee & Coetzee (Pty) Ltd.
Christopher Ranch
Cubist Pharmaceuticals, Inc.
EOAS International
Establecimiento Las Marías
Everest Spices
Everson Spice Company
First Spice Mixing Company
Forest Laboratories, Inc.
Frontier Natural Products Co-op Inc.
Future Generation Co. Ltd
Gautam Export Corporation
Goya Foods, Inc
Hain Celestial Group Inc.
Hangzhou Choisun Tea Sci-Tech Co., Ltd.
Harney & Sons Tea
HDDES Group
Herbal Teas International
Hong Son Cassia & Star Aniseed Processing Co., Ltd.
Hunan Huacheng Biotech Inc.
Hunan Kinglong Bio-resource Inc.
Huong Que Company
Indena
Indus Organics
Industrial Comercial Holguin E Hijos S.A
Integrity Nutraceuticals International Founded
Intercom Limited
Ishana Spice Exports
Jabs International
James Finley
Jinxiang Luteng Trading Company
J. Thomas & Co. Pvt. Ltd
Kancor Ingredients Ltd
K. Patel Phyto Extractions Pvt. Ltd
Kraus
La Flor Spices
Laila Impex
La India Packing Company
Laxmi Enterprises
L B Spices Trading (Private) Limited
LEROS Herbal Teas
Lily of the Desert Organic Aloeceuticals
Linnea
Lipton
McCormick & Company, Incorporated
Mcleod Russel India Ltd.
Mahashian Di Hatti Limited
Monteray Bay Spice Company
Mountain Rose Herbs
Nagata Chaen
NHC Foods Ltd.
Numi Organic Tea
Nutraceuticals International LLC
Olam International Limited
Olbas
Organic India
Orient Vietnam Company Limited
Out of Africa Trading
P.C. Kannan & Co.
Peruvian Nature
PT Cassia Co-Op
PT Dwiwarna Inti Sejahtera
Pu-erh Tea Company
Quechua Foods S.A.C.
Qingdao Xintianfeng Foods Co., Ltd
Rathna Producers Cinnamon Exports (Pvt) Ltd.
Reindeer Biotech Co., Ltd
Republic of Tea
Revolution Tea Company
Rishi Tea
Rooibos Limited
Saboor Chatoor (Private) Limited
SAMI LABS Limited
SDS Spices (PVT) Ltd.
Shandong Longtai Fruits and VegeTABLES Co., Ltd.
SNA Tea Company
Spice House USA
Starwest Botanical
Stash Specialty Tea Company
Swani Spice Mills Pvt. Ltd.
Taifeng Foods Co. Ltd.
Taiyo Kagaku Co., Ltd
Tata Global Beverages
Tazo Tea Company
Teavana Holdings, Inc.
TEEKANNE GmbH & Co. KG
Tetley
The Empire Associates
The Garlic Company
The Medicines Company
Time Out Products Inc
Topix Pharmaceuticals
Traditional Medicinals, Inc.
Tripper
Twinings Tea
United Natural Foods, Inc.
Vanns Spices
Van Rees
Vessey
Viet Spice
Whole Foods Market, Inc.
Xuzhou Hongchang Garlic Co., Ltd.
Yerbalatina Phytoactives
Yogi Botanicals
Yogi Tea
YY Tea

TABLES

1.) Global Production of Antibiotics Vs. Medicinal Plants (USD Million): 2014-2019
2.) Microbes Vs. Humans Metrics
3.) Increased Resource Use and Cost Associated with Infection Resistant Rather than Susceptible Microorganisms Since 2000
4.) Annual Cost-of-Illness for Selected Conditions
5.) Global Antibiotics Market (USD Billion): 2014-2019
6.) Global Antibiotics Market by Type (USD Billion): 2014-2019
7.) Global Antibiotics Market by Region (USD Billion): 2014-2019
8.) 83 Global Manufacturers of Antibiotics and Their Websites
9.) Antibiotic Manufacturers Market Shares (USD Million, %): 2014
10.) Leading Antibiotic Manufacturers by Brand and Type
11.) Higher Mortality Rates in Patients with Resistant Bacteria Compared to Susceptible Strains by Type
12.) Gram-negative Competitive Landscape: Marketed Products by Major Manufacturers-2014
13.) Gram-negative Competitive Landscape-Therapies in Development by Major Manufacturers: 2014
14.) Clostridium difficile-associated diarrhea (CDAD) Competitive Landscape: Marketed Products
15.) Clostridium difficile-associated diarrhea (CDAD) Competitive Landscape: Agents in Development
16.) Gram-positive Market Dynamics
17.) Gram-positive with MRSA Coverage Product and Therapies in Development
18.) Categories of Botanical Therapeutics
19.) Antibacterial to MRSA Plants by Class and Type
20.) Antibacterial Medicinal Plants and Their Species
21.) Global Medicinal Plant Production (USD Million): 2014-2019
22.) Global Medicinal Plant Exports by Country (USD Thousand): 2009-2013
23.) Global Medicinal Plant Imports by Country (USD Thousand): 2009-2013
24.) Global Medicinal Plant Production by Selected Types (USD Million): 2014-2019
25.) 554 Exporters of Turmeri: including company name, products traded, country, website
26.) 130 Importers of Turmeric: including company name, products traded, country, website
27.) Curbicin Overview
28.)Tedizolid Overview
29.) Ceftolozane/tazobactam Overview
30.) Dificid Overview
31.) Dificid Overview
32.) Cubist Pharmaceuticals Revenue by Product: 2012, 2013

FIGURES

1.) Antimicrobial Drug Discovery Timeline
2.) Sigmoidal Development of AMR
3.) MRSA and Gram Negative Markets (Million Days of Therapy): 2013
4.) US and 5 EU Countries Days of Therapy Defined by Select IV Antibiotics: Market Share by Product Type
5.) Key Infections Caused by Gram-negative Pathogens: Market Share by Type
6.) Distribution of Gram-negative Pathogens Causing Healthcare-associated Infections by Type in the United States: 2009-2010
7.) Pathogens Causing Infection in the Intensive Care Unit
(% Positive Isolates
8.) Prevalence of Gram-negative Resistance in Urinary Tract Infections (UTIs) in US Hospitals: 2009-2009
9.) Carbapenem Resistance in Gram-negative Pathogens Causing Healthcare-associated Infections in the United States: 2009-2010
10.) Proportion of Escherichia coli Resistant to Fluoroquinolones by Country (%): 2011
11.) Clostridium difficile Overview
12.) Hospital Days of Therapy: US Market Share by Drug (%)
13.) Aggregate Costs for All CDAD-related US Hospital Stays
14.) CDAD Recurrence Rates And Physician Concerns
15.) Structures of Plant Antimicrobials and MDR Inhibitors
16.) Berberis fremontii, Which Produces berberine and 5'-methoxyhydnocarpin
17.) Traditional Targets of Antimicrobial Compounds
18.) Model of Biofilm Development
18.) Model of Biofilm Development
19.) Cumulative Sales of U.S. I.V. Antibiotics Post Launch by Brand for First 121
Months
20.) Cubicin US Net Revenues: 2003-2013
21.) Cubicin US Market Share (Based on Days of Therapy): 2013
22.) Cubicin Hospital and Out-Patient US Revenue: 2011-2013
23.) Cubicin Usage by Indication Measured by Days of Therapy: 2013
24.) Tedizolid Compared To Pfizer's Zyvox And Generic Vancomycin
25.) Ceftolozane/tazobactam In Vitro Spectrum
26.) Resistance Mechanisms: Pseudomonas aeruginosa and Escherichia coli
27.) Dificid® Mechanism of Action
28.) The Medicines Company's Focus on 3000 Hospitals Worldwide
29.) The Medicine Company's New Antibiotics and the Threats They Address
30.) S aureus: A Unique Organism
31.) A Short List of MRSA Infections
32.) ABSSSI Antibiotics: FDA Approved, Investigational Agents and Nontraditional